Since ER-positive BC accounts for approximately 75% of the BC population, applying receptor targeted nuclear imaging and/or therapy using GRPR or SSTR2 radioligands could be beneficial for the majority of the BC population [2]. Here, SSTR2 is linked to breast cancer.